JP2024529457A - 生弱毒化細菌を用いたがん療法 - Google Patents

生弱毒化細菌を用いたがん療法 Download PDF

Info

Publication number
JP2024529457A
JP2024529457A JP2024505007A JP2024505007A JP2024529457A JP 2024529457 A JP2024529457 A JP 2024529457A JP 2024505007 A JP2024505007 A JP 2024505007A JP 2024505007 A JP2024505007 A JP 2024505007A JP 2024529457 A JP2024529457 A JP 2024529457A
Authority
JP
Japan
Prior art keywords
composition
live attenuated
cancer
bacterium
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529457A5 (https=
Inventor
デバン，リヴィヤ
グランヴィル，ニコラス
Original Assignee
プロカリウム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロカリウム リミテッド filed Critical プロカリウム リミテッド
Publication of JP2024529457A publication Critical patent/JP2024529457A/ja
Publication of JP2024529457A5 publication Critical patent/JP2024529457A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024505007A 2021-07-28 2022-07-28 生弱毒化細菌を用いたがん療法 Pending JP2024529457A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21188352.5A EP4124342A1 (en) 2021-07-28 2021-07-28 Cancer therapy with live attenuated bacteria
EP21188352.5 2021-07-28
PCT/EP2022/071198 WO2023006879A1 (en) 2021-07-28 2022-07-28 Cancer therapy with live attenuated bacteria

Publications (2)

Publication Number Publication Date
JP2024529457A true JP2024529457A (ja) 2024-08-06
JP2024529457A5 JP2024529457A5 (https=) 2025-05-21

Family

ID=77126585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505007A Pending JP2024529457A (ja) 2021-07-28 2022-07-28 生弱毒化細菌を用いたがん療法

Country Status (7)

Country Link
US (2) US12171791B2 (https=)
EP (2) EP4124342A1 (https=)
JP (1) JP2024529457A (https=)
CN (1) CN117729929A (https=)
AU (1) AU2022318153A1 (https=)
CA (1) CA3226844A1 (https=)
WO (1) WO2023006879A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118045167A (zh) * 2024-02-18 2024-05-17 绍兴越然生物医药科技有限公司 抗肿瘤复合疫苗

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
GB9910812D0 (en) 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
WO2003063593A1 (en) 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
US20070298012A1 (en) 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
CA2714276A1 (en) 2008-02-05 2009-08-13 Aeterna Zentaris Gmbh Recombinant bacteria with e. coli hemolysin secretion system and increased expression and/or secretion of hlya, process of manufacturing and uses thereof
GB0900350D0 (en) 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
EP2801364A1 (en) * 2013-05-07 2014-11-12 Centre Hospitalier Universitaire Vaudois (CHUV) Salmonella strain for use in the treatment and/or prevention of cancer
EP3495469A1 (en) 2017-12-07 2019-06-12 Prokarium Limited Vaccine compositions ii

Also Published As

Publication number Publication date
WO2023006879A1 (en) 2023-02-02
US20240226190A1 (en) 2024-07-11
EP4376861A1 (en) 2024-06-05
US12171791B2 (en) 2024-12-24
CA3226844A1 (en) 2023-02-02
US20250064866A1 (en) 2025-02-27
EP4124342A1 (en) 2023-02-01
CN117729929A (zh) 2024-03-19
AU2022318153A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
JP2017500341A (ja) 新生物疾患の処置、減少、阻害、又は制御において使用するための、免疫調節薬
JP7247097B2 (ja) がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン
CN114375331B (zh) 用于脑肿瘤治疗的溶瘤性i型单纯疱疹病毒
US20250064866A1 (en) Cancer therapy with live attenuated bacteria
US12214001B2 (en) Cancer therapy
KR20240015038A (ko) 인터루킨-21의 분비를 위한 재조합 발현 벡터 및 이로형질전환된 약독화 살모넬라 균주
TWI868410B (zh) 用於腦腫瘤治療的溶瘤性ｉ型單純皰疹病毒
US20260000716A1 (en) Methods and compositions for the treatment of cancer
HK40092586A (zh) 用於脑肿瘤治疗的溶瘤性i型单纯疱疹病毒
JP2023551645A (ja) がん治療における使用のためのマイコバクテリウム
HK40068989B (en) Oncolytic herpes simplex type 1 viruses for treatment of brain tumors
HK40068989A (en) Oncolytic herpes simplex type 1 viruses for treatment of brain tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250512